GT Biopharma

Historical price data

GT Biopharma is a micro-cap biotech focused on developing next-generation NK cell engagers via its proprietary TriKE® platform. The company's strategy centers on leveraging this modular technology to create potent, off-the-shelf immunotherapies that direct a patient's innate immune system against cancer. Key achievements include the ongoing Phase 1 trial for GTB-3650 in AML/MDS and the planned initiation of a Phase 1 trial for GTB-5550 in solid tumors in mid-2026. GT Biopharma's approach aims to differentiate from T-cell focused therapies by potentially offering a safer, more readily deployable treatment modality.

The Tri-specific Killer Engager (TriKE®) platform engineers single-chain proteins that bridge natural killer (NK) cells to cancer cells via dual targeting domains (e.g., anti-CD16 & anti-tumor antigen) and incorporates an interleukin-15 (IL-15) moiety to stimulate NK cell proliferation, survival, and killing activity.